Veri MedTech Holdings, Inc. Form S-1/A — Sep 18, 2026
Veri Medtech Holdings (VRHI) filed an amended S-1 for a firm commitment IPO of up to 3,750,000 shares at an assumed $4.00 per share, expected to gross about $15 million and net roughly $11.9 million after a 7% underwriting discount, 2% corporate finance fee, warrants, and expenses.
Key figures
- Revenue
- ~$11,000,000 FY2025 vs ~$17,000,000 FY2024
- Net Income
- -$2,320,000 FY2025 vs -$409,000 FY2024
- Gross Proceeds
- $15,000,000 gross / ~$11,948,000 net ($17,250,000 gross / ~$13,996,000 net with full over-allotment)
- Offering Price
- $4.00 (assumed)
- Shares Offered
- 3750000
- Shares Outstanding
- 8,000,004 pre-offering; 11,750,004 post-offering
- Employees
- 25
- Card fee range
- $100-$200 per card
- H1 2026 revenue
- $4,480,000 (vs $6,115,000 H1 2025)
- Q2 2026 revenue
- $2,043,000 (vs $2,844,000 Q2 2025)
- Greenshoe shares
- 562500
- H1 2026 net loss
- $496,000 (vs $743,000 H1 2025)
- Reverse split ratio
- 1-for-2.5 (effected Sept 2, 2026)
- Corporate finance fee
- 2% of gross proceeds
- Underwriting discount
- $1,050,000 (7%)
- Warrant exercise price
- $4.80 (120% of offering price)
- Last reported otc price
- $5.00 (Sept 17, 2026)
- Buyback authorization shares
- 3000000
- Representative warrant shares
- 187500
- Accumulated deficit jun30 2026
- $5,338,000
- Stockholders deficit jun30 2026
- $2,733,000
- Marijuanadoctors acquisition 2022
- $3,000,000
- Non accountable expense allowance
- $300,000
- Working capital deficit jun30 2026
- $2,457,000
- Underwriter expense reimbursement cap
- $150,000
AI analysis
Red flags9 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.